Chemotherapy is recommended for limited-stage small cell lung cancer as long as it can be tolerated by the body. Surgery combined with postoperative adjuvant chemotherapy is recommended for limited-stage small cell lung cancer without mediastinal lymph node metastasis, while simultaneous radiotherapy or sequential radiotherapy is recommended for limited-stage small cell lung cancer with mediastinal lymph node metastasis. 1. Limited-stage small cell lung cancer without mediastinal lymph node metastasis: small cell lung cancer has high malignancy, is prone to recurrence and metastasis, and has a poor prognosis. Small cell lung cancer without mediastinal lymph node metastasis is recommended to be treated by surgery combined with postoperative adjuvant chemotherapy after systematic staging, and the chemotherapy is often used to reduce recurrence and metastasis by etoposide combined with platinum-based regimen. 2. Limited-stage small cell lung cancer with mediastinal lymph node metastasis: limited-stage small cell lung cancer with mediastinal lymph node metastasis (beyond T1-2N0 but still confined to the ipsilateral thorax) has limited effect of surgical treatment, and most of them adopt synchronous radiotherapy or sequential radiotherapy, and chemotherapy is also commonly used in combination with platinum-based regimen of etoposide, which can improve the local control rate, reduce the distant metastasis rate and improve the prognosis. Therefore, chemotherapy is recommended in limited stage of small cell lung cancer if the physical status is still good and can tolerate chemotherapy, and the chance of chemotherapy is very high, but because of the toxicity associated with chemotherapy, patients who are older and cannot tolerate chemotherapy or have serious liver and kidney function damage should not be forced to take chemotherapy, and it is recommended that patients choose the suitable treatment for themselves under the guidance of doctors.